Laboratorio di Diagnosi e Terapia delle Malattie Lisosomiali, Department of Women's and Children's Health, University of Padova, Padova, Italy.
Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.
Eur J Pediatr. 2019 May;178(5):739-753. doi: 10.1007/s00431-019-03341-8. Epub 2019 Feb 26.
Mucopolysaccharidoses (MPS) are a subgroup of 11 monogenic lysosomal storage disorders due to the deficit of activity of the lysosomal hydrolases deputed to the degradation of mucopolysaccharides. Although individually rare, all together they account for at least 1:25,000 live births. In this study, we present the genetic analysis of a population of 71 MPS patients enrolled in a multicenter Italian study. We re-annotated all variants, according to the latest recommendations, and re-classified them as suggested by the American College of Medical Genetics and Genomics. Variant distribution per type was mainly represented by missense mutations. Overall, 10 patients had received no molecular diagnosis, although 6 of them had undergone either HSCT or ERT, based on clinical and enzymatic evaluations. Moreover, nine novel variants are reported.Conclusions: Our analysis underlines the need to complete the molecular diagnosis in patients previously diagnosed only on a biochemical basis, suggests a periodical re-annotation of the variants and solicits their deposition in public databases freely available to clinicians and researchers. We strongly recommend a molecular diagnosis based on the analysis of the "trio" instead of the sole proband. These recommendations will help to obtain a complete and correct diagnosis of mucopolysaccharidosis, rendering also possible genetic counseling. What is known • MPS are a group of 11 metabolic genetic disorders due to deficits of enzymes involved in the mucopolysaccharides degradation. • Molecular analysis is commonly performed to confirm enzymatic assays. What is new • Eighty-six percent of the 71 patients we collected received a molecular diagnosis; among them, 9 novel variants were reported. • We stress the importance of molecular diagnosis in biochemically diagnosed patients, encourage a periodical re-annotation of variants according to the recent nomenclature and their publication in open databases.
黏多糖贮积症(MPS)是一组 11 种单基因溶酶体贮积症中的一种,其病因是溶酶体水解酶活性缺失,导致黏多糖降解障碍。尽管每种疾病的发病率都较低,但所有 MPS 疾病的总发病率至少为 1:25000。在本研究中,我们对参与意大利多中心研究的 71 名 MPS 患者的遗传数据进行了分析。我们根据最新的建议重新注释了所有变异,并根据美国医学遗传学与基因组学学院的建议对其进行了重新分类。根据类型,变异的分布主要以错义突变为主。总体而言,有 10 名患者未接受分子诊断,尽管其中 6 名患者根据临床和酶学评估,已接受过 HSCT 或 ERT。此外,还报告了 9 个新的变异。
我们的分析强调了有必要对以前仅根据生化结果进行诊断的患者完成分子诊断,建议定期重新注释变异,并将其免费提交至可供临床医生和研究人员使用的公共数据库中。我们强烈建议基于“三联体”而非单纯的先证者进行分子诊断。这些建议将有助于对黏多糖贮积症进行全面、准确的诊断,同时也能够进行遗传咨询。
MPS 是一组 11 种代谢性遗传疾病,其病因是参与黏多糖降解的酶缺乏。
通常进行分子分析以确认酶分析的结果。
我们收集的 71 名患者中,86%接受了分子诊断;其中,报告了 9 个新变异。
我们强调了在生化诊断患者中进行分子诊断的重要性,鼓励根据最新命名法定期重新注释变异,并将其发表在开放数据库中。